Hone your leadership qualities and adapt your approach to business challenges to enhance your performance and benefit your organisation.
UCL Biochemical Engineering pioneered the VISION Leadership Programme in 2010 to cater specifically for individuals at management and executive levels within the bioindustry.
VISION provides leadership insights through intellectual analysis and intensive, practical learning to provide you with the tools required to drive innovation, entrepreneurship and global leadership in your organisation.
VISION addresses critical drivers facing the sector which create unique strategic challenges, including: IP, portfolio management, integrating new technologies, adapting to regulatory requirements, managing risks and speed to market. Designed for high-impact individuals, VISION provides key leadership insights tailored for present and future leaders in the bioindustry. This is achieved through rigorous intellectual analysis and practical peer-to-peer action based learning, which provides the required tools to drive innovation, entrepreneurship and leadership in organisations.
University College London is one of the world's top multidisciplinary universities, with an international reputation for the quality of its research and teaching. The Department of Biochemical Engineering is acknowledged as the UK Centre of Excellence in the field. Our research addresses challenges in three key sectors of the advanced bioprocessing industries: industrial biotechnology, macromolecular medicines and cell therapy bioprocessing. Due to our strong international reputation, we are uniquely positioned to partner with key industrial leaders to create an innovative programme.
VISION is recommended for:
- Managers and practitioners fast tracked for executive roles or intending to move into leadership positions.
- Current executives intending to interact with fellow leaders and expert speakers to debate and exchange novel thoughts and opinions.
- Funding agencies wanting to interact with present and future thought leaders to gain insights into the sector trends and skills required to navigate the changing bioindustry landscape.
- Prof Eli Keshavarz-Moore: Professor of Bioprocess Science and Enterprise, Vice-Dean (International), University College London
- Dr Naveraj Gill: Strategic Alliance Director, University College London
- Speaker Biographies
Dr Kym Baker: General Manager, Patheon Biologics Australia
Patheon is a contract manufacturer of biological parental products produced from mammalian cell lines for both ongoing clinical trials and commercial drug manufacture serving a worldwide market. Dr Baker has a strong academic and commercial background, holding a variety of positions in the biotechnology and biopharmaceutical industry for >20 years in the UK. Following Industrial sponsored post-doctoral studies at the University College of London and University of Kent working with Celltech (now UCB), GSK, British Biotech and Lonza, Kym joined the management team in Lonza, UK holding a variety of senior positions across both development, manufacturing and quality. Returning to Australia, Dr Baker took up the GM role in Patheon. Dr Baker graduated with 1st class Honours from the first ever intake of University of QLDs Bachelor of Applied Science Biotechnology programme then obtained her PhD from the Australian National University in Canberra based in CSIRO. Dr Baker is passionate about science education and the development of future scientific and engineering talent to help grow the Biotechnology industry in Australia through improved collaboration between industry and academia.
Chris Nave: Managing Director, Brandon Capital Partners
Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.
Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry.
In October 2014, Chris was awarded the AusBiotech Johnson & Johnson Industry Leadership Award, announced during the Ausbiotech Conference on the Gold Coast.
Chris is currently a Director of OccuRx Pty Ltd, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, Athena Medicines, QueOncology Pty Ltd, Azura Ophthalmics and Cardiora Pty Ltd. Chris was also Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.
Dr Rahul Singhvi: CEO, Takeda Vaccines
Rahul Singhvi is Chief Operating Officer of Takeda’s Global Vaccine Business Unit and is responsible for global supply of vaccines at the Takeda Pharmaceutical Company.
Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. a Nasdaq-listed biotechnology company (NVAX). During his tenure at Novavax, Dr. Singhvi transformed the company from a specialty pharmaceutical business to a premier vaccine company and increased its valuation from $30M to over $300M over his tenure as CEO. Dr. Singhvi’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing. At Merck, he co-lead a project team that oversaw the development of Varivax®III (chickenpox vaccine), ProQuad® (MMRV pediatric combination vaccine) and Zostavax® (Shingles vaccine). Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his MS and ScD chemical engineering degrees from MIT. He received an MBA degree from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.
Professor Barry Buckland: CEO, BiologicB; Ex-VP Merck Research Laboratories
PhD in Biochemical Engineering at University College London obtained in 1974. Joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group. Leader of process development of all biologically made product candidates within the MRL pipeline and manufacture of Clinical Supplies during a 20 year time frame. Products developed within this period include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine).
External awards and appointments include being elected to the National Academy of Engineering in 1997 and Fellow of University College London in 1998. Awards include the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award: Member of team to receive Vaccine Award for Gardasil® in 2007, Merck Board of Directors Award for leading process development for licensure of four (4) new vaccines in 2007. Chaired two International Conferences on Cell Culture (Cell Culture Engineering IV and Cell Culture Engineering V) and co-chaired the first three International Conferences on Metabolic Engineering. Co-chaired the first four International Conferences on Vaccine Technology. Author or co-author of over 70 papers. Visiting Professor at University College London for past 15 years. In October 2008, named by AIChE as one of the "One Hundred Chemical Engineers of the Modern Era" (defined as from World War II to Present) as part of the AIChE Centennial Celebration in Philadelphia, USA and also awarded Marvin Johnson Award by ACS (American Chemical Society) for lifetime contribution to Biotechnology. Awarded PhRMA Discoverer of the Year award in April, 2009 for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen).
Starting in May 2009; CEO, BiologicB. Since this time have provided consultancy worldwide to a number of companies and not-for-profit institutions, in all areas of Biologics including Vaccines, Therapeutic Proteins and Cell Therapy.Chair of Board for a not-for-profit organization, Engineering Conferences International. Continue as Visiting Professor at University College London. Co-Founder of start-up company Enumeral Biomedical. Head, Bioprocess Development at Protein Sciences. The first recombinant Influenza vaccine, Flublok, was licensed in January 2013. Appointed Executive Director of NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) in February, 2017.
Vicki Salmon: Director, IP Asset
Vicki joined IP Asset in January 2009, having previously worked in an International law firm. Vicki is unusual in being both a patent attorney and a solicitor. She has over 30 years’ experience in relation to matters involving intellectual property.
She has particular experience in helping clients to manage IP portfolios, IP disputes and IP in corporate transactions, but also advises on IP strategy, obtaining patent, trade mark & design protection, IP due diligence, including ownership and assignment of rights, commercialisation and enforcement.
A biochemist by training, she is European and British patent attorney, a European Trade Mark and Design Attorney, a Patent Attorney Litigator and a solicitor. She was included in Managing Intellectual Property’s 2016 List of the top 250 global women in IP, and remains in the Managing Intellectual Property IP Stars list for 2017 and 2018. She took part in the BBC’s Radio 4 Programme “The Bottom Line” chaired by Evan Davis on Corporate Espionage (or IP theft) in June 2017.
Vicki is a member of the Council of the Chartered Institute of Patent Attorneys and chairs its Litigation Committee, as well as sitting on a number of other committees. On behalf of CIPA, she has lobbied for changes in IP law, most recently in connection with Brexit and the potential implementation of the Unitary Patent and Unified Patents Court. She was part of the advisory group to the Law Commission’s review of the law of groundless threats of IP litigatio, which led to a change in the law in 2017.
She is also a contributor to practitioner level patent text books: the CIPA Guide to the Patents Act 1977 (Sweet & Maxwell) and the Modern of Law of Patents (Butterworths).
Neil Weir: CEO, Sitryx
Neil Weir is CEO of Sitryx , a biopharmaceutical company based in Oxford UK and focussing on discovering first in class therapeutics arising from a greater understanding of immunometabolism. Prior to joining Sitryx Neil was SVP Research at UCB Pharma for 14 years overseeing the Discovery of small molecule and antibody based therapeutics across UCB’s therapeutic areas of immuno inflammation, bone and neurology . Neil joined UCB from Celltech a UK biotechology company where he had been head of research. During his time at UCB and Celltech Neil and his teams have brought over 35 molecules into clinical development including the marketed drugs Cimzia and Besponsa . Neil is also a co-inventor of several antibody technologies including the first dual signalling domain chimeric receptor now referred to as second generation CAR T.
Neil has also taken an active interest in developing the positive environment for drug discovery and development in the UK and amongst other appointments was chair of the ABPI innovation board between 2012 and 2017 and member of the MRC translation research group. Neil is a non exec board member of Ondek , an Australian biotech company focussed on H Pylori immune regulation and The RNA Medicines company based in Boston MA.
Charles Cooney: Professor Emeritus Chemical and Biochemical Engineering, MIT
Charles L. Cooney, the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering is also the Faculty Director of the Deshpande Centre for Technological Innovation, Emeritus. He received his Bachelor's degree in Chemical Engineering from the University of Pennsylvania, Master's and Ph.D. in Biochemical Engineering from MIT. After a short post-doctoral time at the Squibb Institute for Medical Research he joined the MIT faculty as an Assistant Professor in 1970 and became a full Professor in 1982. He received the 1989 Gold Medal of the Institute of Biotechnological Studies (London), the Food, Pharmaceutical and Bioengineering Award from the American Institute of Chemical Engineers and the James Van Lanen Distinguished Service Award from the American Chemical Society's Division of Microbial and Biochemical Technology, was elected to the American Institute of Medical and Biochemical Engineers and in 2009 elected to the first class of American Chemical Society Fellows. He serves as a consultant to a number of biotech and pharmaceutical companies, is on multiple editorial boards, sits on the Boards of Directors of Axcella, Boyd Technologies, Levitronix, Mitra RxDx, GreenLight Bioscience, Innovent Biopharmaceuticals (China) and enEvolv; he was previously on the Boards of Genzyme, Biocon, Ltd (India), Pall Corp., Cuno, Inc.,Polypore International, Inc and Astra AB. He chaired the FDA Advisory Committee for Pharmaceutical Science from 2004-2006.
Prof. Cooney's research and teaching interests span a range of topics in biochemical engineering and pharmaceutical manufacturing. He has published over 250 research papers, over 25 patents and co-authored or edited 5 books including Development of Sustainable Bioprocesses: Modeling and Assessment, Wiley Press 2006. He research interest include manufacturing in the pharmaceutical, bioprocess and biofuels industries, as well as bioprocess design, operation and control, and processing of pharmaceutical powders and technological innovation strategy. His teaching has focused on bioprocessing, drug development and technological innovation. As founding faculty director of the Deshpande Centre he is interested in the process of stimulating technological innovation and translating innovation into new company creation
VISION at UCL provides an opportunity for senior leaders in the life science industries to do a deep dive into the current and pressing issue of this industry. The interactive three day format provides a forum to ask the difficult questions at the heart of this dynamic industry and explore innovative solutions. Why, at a time of unprecedented scientific discovery is the research productivity of the industry falling?
How can we extract, translate and apply the lessons from building new companies into an established industry? The focus on innovation in a virtual and politically diverse world provides real-time learning. The participants bring a diverse perspective on the issues facing the industry and the resulting discussion provided fascinating and insightful answers that greatly sharpened by thinking on problems at hand. As a consequence of the interaction with colleagues and faculty, this course builds a community that together develop a deeper understanding of the issues as well as the strategies to navigate the path forward." - Professor Charles Cooney, MIT
"VISION is a ground-breaking programme specifically tailored for Senior Executives in biopharma. The courses, briefings and workshops provide invaluable insights into the major challenges faced at Executive Team level every day. They also highlight the opportunities and creative solutions that can be utilised to tackle those challenges head on. I thoroughly recommend it." - Dr Neil Weir, CEO, Sitryx
"What sets the VISION programme apart from other courses in the leadership and innovation space is the bio-industry –focused approach, teaching through real cases studies taught by current leaders who have experienced first-hand how it is done and what pitfalls to avoid." - Rahul Singhvi, Takeda Vaccines
- Benefit for your Organisation
- Maximise team building, facilitate joint learning and strategic alignment when several key members from an organization attend VISION together
- Complement in-house training for succession planning and talent development
- Gain key considerations for driving and navigating changes in business to stay ahead
- Enhance agility of your organization and how to translate knowledge into commercial benefit
- Access tools for effectively working across a multi- disciplinary business, holistically identify problems, formulate strategies and adapt to change
- Benefit for you
- Know how to make the transition from science and engineering based decision making towards company-wide strategic solutions
- Build an invaluable network with peers and experts from academia and industry who challenge, stimulate and inspire you
- Gain perspectives on leadership challenges and critical business issues facing bioindustry globally and formulate actions to address these
- Learn from real life cases studies how to succeed in making difficult decisions, also devising and implementing strategies to secure a more robust future for your business
- Access and share best practices from experts on how to be a good leader and avoid pitfalls in constantly evolving market
- Achieve your personal development and career objectives
- Evaluate the impact of key innovative research and technologies on the future of business and manufacturing